Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.42 | N/A | +0.06% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.42 | N/A | +0.06% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on their product pipeline. However, the lack of specific guidance may have left some investors uncertain.
Management expressed confidence in the pipeline but did not provide specific guidance.
They highlighted ongoing investments in research and development.
AbbVie's earnings report showed a slight beat on EPS, which is a positive sign for the company. However, the stock fell by 1.8% likely due to the absence of revenue details and future guidance. Investors may be cautious as they await more information on the company's performance and strategy moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CATERPILLAR INC
Jul 25, 2017